Pharma BD Deal Intelligence
Biogen acquired HI-Bio for $1.15B for monoclonal antibody pipeline.
Biogen beefs up immuno pipeline with potential $1.8B HI-Bio acquisition gaining felzartamab.
Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio for felzartamab.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Biogen acquired HI-Bio for $1.15B for monoclonal antibody pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Human Immunology Biosciences (this deal) | 2024 | $1.1B | 68 |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
| Biogen Inc. / Vanqua Bio, Inc. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2024 deals · Biogen Inc. deals · Immunology deals